Generex NuGenerex-Dr. Tamera Coyne-Beasley, MD, MPH, FAAP, FSAHM is the Derrol Dawkins, MD Endowed Chair in Adolescent Medicine at Children’s of Alabama, Professor of Pediatrics and Internal Medicine, Director of the University of Alabama at Birmingham Division of Adolescent Medicine, and Vice Chair of Pediatrics for Community Engagement
MIRAMAR, Fla., Oct. 30, 2020 (GLOBE NEWSWIRE) — Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) ( https://www.otcmarkets.com/stock/GNBT/quote ) today announced that Dr. Tamera-Coyne Beasley has joined the NGIO COVID-19 Vaccine Scientific & Clinical Advisory Board (SAB) to help guide the company’s efforts in developing clinical research protocols that address the unmet medical and social needs of adolescents and young adults, who have been shown to transmit the coronavirus. She will also be instrumental in helping the company with community outreach programs, particularly in communities of color who are at increased risk of infection and the serious complications of COVID-19.
Dr. Coyne-Beasley completed her undergraduate work at Brown University before receiving her Master’s in Public Health in Epidemiology at the University of North Carolina at Chapel Hill and graduating from Duke University Medical School. She is currently a Professor of Pediatrics and Internal Medicine, practicing physician in the William A. Daniel, Jr. Adolescent Health Center at Children’s of Alabama and Director of the University of Alabama at Birmingham Division of Adolescent Medicine. Dr. Coyne-Beasley is also the Vice Chair of Pediatrics for Community Engagement. As a key opinion leader in the field of adolescent medicine, Dr. Coyne-Beasley is Past President of the Society for Adolescent Health and Medicine.
Generex CEO, Joseph Moscato said, “We are honored that Dr. Coyne-Beasley has joined our scientific and clinical advisory board. Her extensive experience and expertise in treating adolescents is especially important at this time of the coronavirus pandemic, as the opening of schools and universities has resulted in nationwide COVID spikes, clearly demonstrating the need for a vaccine that can be safely administered to children, adolescents, and young adults. And through her work in community engagement, we will further our efforts to include underserved communities who have been disproportionately impacted by the pandemic. We look forward to working closely with Dr. Coyne-Beasley as we advance the Ii-Key-SARS-CoV-2 vaccine into the clinic.”
About NuGenerex Immuno-Oncology
NuGenerex Immuno-Oncology, a subsidiary of Generex Biotechnology, is a clinical stage oncology company developing immunotherapeutic peptide vaccines for cancer and infectious disease based on the CD4 T-Cell activation platform, Ii-Key. NuGenerex Immuno-Oncology (NGIO) has been spun out of Generex as a separate public company to advance the platform Ii-Key technology, particularly in combination with the immune checkpoint inhibitors for the treatment of cancer. NGIO is currently engaged in a Phase II clinical trial of its lead cancer immunotherapeutic vaccine AE37 in combination with pembrolizumab (Merck’s Keytruda®) for the treatment of triple negative breast cancer. The company has also turned its Ii-Key technology on infectious disease, responding to the coronavirus pandemic with a SARS-CoV-2 vaccine development program.
About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.
Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as “expects,” “plan,” “believes,” “will,” “achieve,” “anticipate,” “would,” “should,” “subject to” or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.